Cancer reports最新文献

{"title":"Gastric Cancer Literacy and Related Factors in Iran: A Cross-Sectional Study.","authors":"Fatemeh Pourhaji, Mohammad Hossein Delshad, Kianoosh Yavarmanesh","doi":"10.1002/cnr2.70486","DOIUrl":"10.1002/cnr2.70486","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is one of the most prevalent and deadly cancers worldwide, particularly in countries like Iran. Gastric cancer health literacy (GCHL) plays a key role in early detection, prevention, and timely treatment. This study aims to investigate the level of GCHL and its associated factors among adults in Torbat Heydarieh, northeastern Iran.</p><p><strong>Methods: </strong>In this cross-sectional study conducted from January 5, 2022, to September 26, 2023, 304 clients from Comprehensive Health Service Centers (CHSCs) in Torbat Heydarieh were surveyed. Data were collected using a validated tool that measured sociodemographic characteristics and Gastric cancer health literacy questionnaire (GCHLQ), knowledge of risk factors, symptoms, prevention methods, and screening, and attitude questionnaire included beliefs about GC prevention, curability at early stages, the benefits of early detection, previous screening history, and reasons for not undergoing screening. Data were analyzed using SPSS software version 25 using descriptive statistics, correlation tests, and multiple linear regression to determine predictors of GCHL. The statistical significance level was set at p < 0.05.</p><p><strong>Results: </strong>Participants demonstrated a moderate (31-39) level of GCHL. Higher GCHL scores were significantly associated with being female, having a higher educational level, and a family history of GC. The multivariate regression model explained 51.4% of the variance in GCHL. In this model, family history of GC, knowledge score, and female gender were significantly associated with higher GCHL scores.</p><p><strong>Conclusions: </strong>The findings emphasize the importance of targeted educational and awareness programs to improve GCHL, particularly among older adults and rural populations. Future longitudinal and qualitative studies are recommended to better understand barriers to cancer literacy and improve health outcomes through informed interventions.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70486"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder Cancer Incidence Trends in the United States From 2000 to 2020.","authors":"Seyed Ehsan Mousavi, Ryan Michael Antar, Armin Aslani, Pourya Shokri, Zahra Yekta, Amin Bateni, Nasser Shakhssalim, Seyed Aria Nejadghaderi","doi":"10.1002/cnr2.70548","DOIUrl":"10.1002/cnr2.70548","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is one of the most common urogenital cancers globally. Here, we aimed to report the incidence trend of bladder cancer in the United States (US) over 2000-2020, by age, sex, race/ethnicity, and types using Surveillance, Epidemiology, and End Results (SEER).</p><p><strong>Methods: </strong>We used SEER 22 data to calculate the age-standardized and delay-adjustment incidence rate of bladder cancer. Only individuals diagnosed with cancer and whose age at diagnosis was known were included in the study. A delay model was applied, adjusting for variables such as cancer site, registry, age group, race/ethnicity, and year of diagnosis. Using the Tiwari technique, the same database was also used to determine the age-standardized incidence rate (ASIR) of subtypes. The incidence data for 2020 were excluded from Joinpoint trends while displayed separately in illustrations.</p><p><strong>Results: </strong>Over 2000-2019, most bladder cancer cases were urothelial carcinoma (92.99%), among non-Hispanic Whites (84.48%) and those aged 70 to 84 years (45.72%). There was a significant decrease in the ASIR of bladder cancer across all races/ethnicities in both sexes within all age groups (Average annual percent change (AAPC): -0.95%; [-1.06, -0.83] for men and -1.02% [-1.21, -0.84] for women) over 2000-2019. The incidence rates decreased by 6.23% during the COVID-19 pandemic. Also, the delay-adjusted incidence rate of bladder cancer increased with advancing age.</p><p><strong>Conclusions: </strong>Despite a decrease in ASIR of bladder cancer over 2000-2019, there are still a high number of incident cases, particularly among NHWs and the elderly. Future studies should investigate the underlying causes of bladder cancer incidence trends among demographic groups.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70548"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases.","authors":"Paul M Harary, Yusuke S Hori, Ruchit Jain, Ahed H Kattaa, Melanie Hayden Gephart, Michael F Gensheimer, Scott G Soltys, David J Park, Steven D Chang","doi":"10.1002/cnr2.70571","DOIUrl":"10.1002/cnr2.70571","url":null,"abstract":"<p><strong>Background: </strong>Brain metastasis (BM) occurs in < 3% of malignant mesothelioma (MM) cases and is associated with an aggressive disease course. While genomic profiling has provided insight into molecular alterations in MM, the characteristics of MM with brain involvement remain unexplored. Data are particularly limited for MM of pericardial origin, an exceedingly rare tumor which comprises < 1% of mesotheliomas.</p><p><strong>Cases: </strong>We describe the clinical course and genetic profiles of two patients with BM from MM, both of whom exhibited atypical presentations, including neurological symptoms, diagnosis at extremes of age for this condition, and absence of prior asbestos exposure. In Case 1, a 20-25-year-old male with pericardial MM presented for left arm shaking, with brain MRI at this time revealing 14 total lesions, 85.7% of which had vasogenic edema. He underwent whole-brain radiotherapy (WBRT), passing away 21.25 months following initial diagnosis. In Case 2, an 85-90-year-old male reported expressive aphasia and was found to have a large hemorrhagic frontotemporal lesion. He was subsequently diagnosed with pleural MM and received stereotactic radiosurgery (SRS) for management of BM, with a favorable treatment response on follow-up imaging. He succumbed to systemic progression 6 months after diagnosis of BM. Next-generation sequencing identified a missense mutation in RAD51C in Case 1, and NF2 splice-site and TP53 frameshift mutations in Case 2.</p><p><strong>Conclusion: </strong>To our knowledge, this represents the first reported genetic profiling of MM with BM. The TP53 frameshift mutation is unusual for MM, and its potential association with rapid disease progression warrants further investigation. Given the aggressive nature of MM, SRS may be preferable to WBRT due to its shorter treatment time and ease of combination with systemic regimens.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70571"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response.","authors":"Yunxia Chen, Wenyu Zhang, Xiang Gao, Kongling Xing, Yijing Ren, Jinyu Hu, Zhihao Xie, Ping Zhou","doi":"10.1002/cnr2.70539","DOIUrl":"https://doi.org/10.1002/cnr2.70539","url":null,"abstract":"<p><strong>Background: </strong>Oropharyngeal squamous cell carcinoma (OPSCC) accounts for a substantial proportion of head and neck cancers, with a rising incidence largely driven by human papillomavirus (HPV) infection. Despite advances in multimodal treatment, disease recurrence remains common and limits long-term survival, highlighting the need for reliable biomarkers to guide prognosis and treatment.</p><p><strong>Methods: </strong>This review summarizes recent advances in biomarker development in OPSCC across multiple biological domains. We examined molecular biomarkers, including genomic alterations, DNA methylation, and non-coding RNAs; protein biomarkers associated with oncogenic signaling, cell-cycle regulation, apoptosis, inflammation, and angiogenesis; as well as circulating biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome-derived RNA.</p><p><strong>Results: </strong>Among currently available biomarkers, p16, PD-L1, and circulating HPV DNA demonstrate the strongest clinical applicability, particularly for risk stratification and post-treatment surveillance. Emerging evidence also supports the use of combined biomarker panels to improve prediction of treatment response to radiotherapy, chemotherapy, and immunotherapy. However, many candidate biomarkers show inconsistent performance due to methodological variability, limited sensitivity and specificity, and insufficient prospective validation.</p><p><strong>Conclusions: </strong>While several biomarkers show promise in OPSCC, further standardization of detection methods and large-scale prospective studies are required. Integration of multi-omics data with computational approaches, including artificial intelligence, may facilitate the development of robust and clinically actionable predictive models, ultimately enabling more personalized management and earlier detection of recurrence.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70539"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Critical miRNAs miR-4652 and miR-1304 as Novel Diagnostic Markers for Oral Squamous Cell Carcinoma.","authors":"Sara Bagheri Farahani, Ehsan Keramati, Marziyeh Etesami, Faranak Jamshidian","doi":"10.1002/cnr2.70552","DOIUrl":"https://doi.org/10.1002/cnr2.70552","url":null,"abstract":"<p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) is marked by frequent recurrence rates and an unclear etiology, underscoring the critical need for early detection to improve therapeutic outcomes and reduce healthcare costs. MicroRNAs (miRNAs) have emerged as key regulators of oral carcinogenesis by modulating gene expression at the posttranscriptional level and influencing various aspects of cellular physiology.</p><p><strong>Objective: </strong>This study aimed to comprehensively evaluate the prognostic significance of miR-1304 and miR-4652 expression levels in patients with OSCC, and to explore their potential as predictive biomarkers for disease progression and patient survival.</p><p><strong>Methods: </strong>TargetScan was used to predict potential gene interactions of the microRNAs. Subsequently, the expression levels of C-Myc and the microRNAs miR-1304-3p and miR-4652-5p were evaluated in 30 pairs of OSCC and adjacent normal tissue samples. qRT-PCR analyses were performed to compare the expression of these molecules between tumor and normal tissues. Additionally, receiver operating characteristic (ROC) curves were generated to assess the potential diagnostic value of these microRNAs in OSCC.</p><p><strong>Result: </strong>The expression levels of miR-1304, miR-4652, and C-Myc were significantly higher in OSCC tissues compared to their matched adjacent non-tumor tissues (p < 0.0001). Notably, high C-Myc expression was significantly correlated with both tumor grade (p = 0.003) and tumor stage (p = 0.005). ROC curve analysis demonstrated that the areas under the curve (AUCs) for C-Myc, hsa-miR-1304, and hsa-miR-4652 were 0.99, 0.99, and 0.95, respectively (p < 0.0001), indicating strong diagnostic potential.</p><p><strong>Conclusion: </strong>These findings suggest that the upregulation of miR-1304 and miR-4652 could be used as biomarkers in OSCC. However, more studies with large samples are necessary.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70552"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiproliferative Effects of Cannabinoids and Cisplatin in Cervical Cancer Cells.","authors":"S P Mathibela, M T Lebelo, V Steenkamp","doi":"10.1002/cnr2.70561","DOIUrl":"10.1002/cnr2.70561","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer remains a leading cause of cancer-related mortality among women globally, particularly in low- and middle-income countries. Cisplatin, a standard chemotherapeutic agent, is limited by severe toxicities and chemoresistance. This study aimed to assess the effects of cisplatin in combination with phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on cell proliferation, morphology, cell cycle progression, cell death, and DNA damage.</p><p><strong>Methods: </strong>Synergistic interactions between THC, CBD, and cisplatin were assessed in HeLa, SiHa, and MCF-12A cells using the checkerboard assay and SRB assay. Cell morphology, cell cycle progression, apoptosis induction, autophagic activity, and DNA repair gene expression were evaluated using various techniques.</p><p><strong>Results: </strong>The THC-CBD-cisplatin combination exhibited the strongest apoptotic response in cancer cells (HeLa 53%, SiHa 58%), while minimally affecting MCF-12A cells (32%). Cannabinoid co-treatment amplified the antiproliferative and pro-apoptotic effects of cisplatin in HeLa and SiHa cells. The triple combination induced a G2/M arrest in HeLa cells and sub-G1 accumulation in SiHa cells. Autophagic activity, indicated by LC3B puncta formation, increased in HeLa and SiHa cells following THC and CBD exposure. DNA repair genes XRCC1 and RAD51 were downregulated by the cannabinoid-cisplatin combination.</p><p><strong>Conclusion: </strong>These findings demonstrate that combining THC and CBD with cisplatin results in enhanced and mechanistically diverse anticancer effects, with a higher degree of selectivity for cervical cancer cells compared to non-cancerous MCF-12A cells by inducing apoptosis and autophagy while inhibiting DNA repair capacity. This study highlights the potential of cannabinoid-based combination therapies as a promising approach for cervical cancer treatment.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70561"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multidisciplinary Approach for a Patient With Synchronous Lip and Thyroid Cancer Involving Radiotherapy.","authors":"Aleksandra Nasiek, Paweł Polanowski, Marek Hamm, Anna Kozub, Barbara Lipka, Agnieszka Kotecka-Blicharz, Krzysztof Składowski","doi":"10.1002/cnr2.70564","DOIUrl":"10.1002/cnr2.70564","url":null,"abstract":"<p><strong>Background: </strong>Synchronous cancers, defined as malignancies diagnosed concurrently or within 2 months of each other, are rare, with an incidence of 1%-6%. Environmental factors such as tobacco smoking play a significant role in their development. Patients with head and neck squamous cell carcinoma (SCC) are at increased risk of second malignancies, complicating treatment strategies and prognosis. This report presents a rare case of synchronous SCC of the lower lip and papillary thyroid carcinoma (PTC).</p><p><strong>Case: </strong>A 61-year-old male with a history of smoking presented with a 2.5 cm exophytic lesion of the lower lip, diagnosed as keratinizing SCC. A suspicious cervical lymph node was revealed, which intraoperatively demonstrated metastatic PTC. Following partial lip resection and neck dissection, total thyroidectomy was performed, confirming a 1.5 mm PTC focus with micrometastases. The patient underwent adjuvant conventional radiotherapy (RTH) for SCC (66 Gy in 33 fractions) and radioiodine therapy (131-I) for PTC. Post-therapeutic scintigraphy identified suspected micrometastases in the iliac bone, prompting further 131-I treatment. Following completion of therapy, the patient achieved a complete response, with no radiologic or clinical evidence of residual disease from both malignancies.</p><p><strong>Conclusion: </strong>Synchronous SCC of the lip and PTC are exceedingly rare, lacking standardized treatment guidelines. This case highlights the necessity of a multidisciplinary approach, integrating surgery, RTH, and systemic therapy. Careful postoperative histopathological assessment of lymph nodes may reveal unexpected findings that necessitate further diagnostic work-up and a multidisciplinary approach, as this can significantly influence staging, treatment decisions, and patient prognosis, representing an important key learning point.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70564"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual Screening of Traditional Chinese Medicine Natural Product Inhibitors Targeting AQP1 for Bladder Cancer.","authors":"Di Liu, Qing-Yu Zhang","doi":"10.1002/cnr2.70570","DOIUrl":"10.1002/cnr2.70570","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BCa) is the most common and representative type of adult urinary tract urothelial cancer, characterized by high incidence and mortality rates. It has become a major disease threatening public health, highlighting the urgent need for the development of comprehensive treatment strategies, including traditional Chinese medicine, immunotherapy, and genetic diagnostics. Aquaporin-1 (AQP1), a water channel protein, mediates water transport across the cell membrane. Recent studies have shown that aquaporins are involved in the development and progression of malignant tumors. In particular, AQP1 plays a significant role in the pathogenesis of bladder cancer and may serve as a potential target for novel drug development. Natural products, owing to their structural diversity, represent a valuable reservoir of lead compounds for drug discovery.</p><p><strong>Methods and results: </strong>In this study, we employed molecular docking and molecular dynamics simulations to screen a library of 2000 traditional Chinese medicine natural compounds for potential activity against the target protein AQP1. The final analysis identified 17 compounds with high binding affinity for the active site of AQP1, indicating their potential as candidate inhibitors. Among these, compounds 8 (Clematignoside), 10 (Ginsenoside Rb2), and 15 (Tannic acid) demonstrated particularly strong binding affinity and complex stability in molecular dynamics simulations.</p><p><strong>Conclusion: </strong>These findings provide a valuable foundation for the rational design of AQP1-targeted pharmacophores and suggest promising candidates for the future development of clinical drugs for the treatment of bladder cancer. The top-ranked compounds, especially compounds 10 and 15, warrant further experimental investigation.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70570"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological and Prognostic Implications of Epithelial-to-Mesenchymal Transition-Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study.","authors":"Ahmad Machmouchi, Lama Zahreddine, Jessica Aoun, Noura Abbas, Maya Charafeddine, Laudy Chehade, Charbel Elias, Ziad El Husseini, Sally Temraz, Deborah Mukherji, Mohamad Khalife, Walid Faraj, Amar Zaidan, Nayrose Kadi, Ayman Tawil, Ali Shamseddine","doi":"10.1002/cnr2.70565","DOIUrl":"10.1002/cnr2.70565","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) is the sixth leading cause of global cancer death. The process of epithelial-to-mesenchymal transition (EMT) is a key driver of early progression and metastasis in PDAC.</p><p><strong>Aim: </strong>Our study aimed to explore the correlation between the expression of EMT markers and survival outcomes.</p><p><strong>Methods and results: </strong>We conducted a retrospective longitudinal study on patients diagnosed with resectable PDAC between January 2005 and June 2019, with a 5-year follow-up for survival analysis. Immunohistochemical staining was performed to assess E-cadherin and vimentin expression. EMT was defined as the presence of high Vimentin (mesenchymal) expression combined with low E-cadherin (epithelial) expression. The study cohort included 135 patients with resectable PDAC, with 86 males (63.7%) and a mean age of 63.5 years (SD 10.1); most tumors were grade 2 (84, 64.6%). Cox regression analysis revealed that Vimentin expression (p = 0.005), positive margin (p = 0.008), and absence of metformin intake (p = 0.023) were independent predictors of poor OS. High Vimentin was associated with lower median OS (17.0 ± 4.4 vs. 25.8 ± 2.3 months, p = 0.037) and DFS (8.6 ± 1.2 vs. 13.0 ± 2.3 months, p = 0.014), compared to low Vimentin, and it was correlated with higher tumor grade (p = 0.028) and metastasis rate (p = 0.032). The poorest outcomes were observed when high Vimentin was coupled with low E-cadherin (median OS of 12.6 ± 4.7 vs. 24.5 ± 2.1 months, p = 0.038; median DFS of 9.5 ± 0.5 vs. 10.8 ± 2.1 months, p = 0.029), compared to the rest of the population.</p><p><strong>Conclusion: </strong>Our findings showed that Vimentin overexpression and the EMT phenomenon are strongly associated with poor OS and DFS in resectable PDAC, underscoring their potential as prognostic biomarkers and therapeutic targets.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70565"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Prognostic Significance of Activation-Induced Cytidine Deaminase in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP.","authors":"Mardiah Suci Hardianti, Nungki Anggorowati, Syahru Agung Setiawan, Miraz Radhea Bagaskoro, Johan Kurnianda, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Susanna Hilda Hutajulu","doi":"10.1002/cnr2.70557","DOIUrl":"10.1002/cnr2.70557","url":null,"abstract":"<p><strong>Background: </strong>A number of studies have demonstrated the important role of activation-induced cytidine deaminase (AID) in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.</p><p><strong>Aims: </strong>This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen.</p><p><strong>Methods and results: </strong>Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006).</p><p><strong>Conclusion: </strong>The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70557"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}